Brought to you by 
Series C round brings $30mm to Pathwork Diagnostics
24 Sep 2020
Executive Summary
New buyer Alta Partners led a $30mm Series C round for Pathwork Diagnostics Inc. (molecular tests for cancer), and takes a seat on the company's board. Existing investors Abingworth, Advent Venture Partners, Novus Ventures, Prospect Venture Partners, and Venrock also participated. Pathwork will use the proceeds to launch its Pathwork tissue-of-origin diagnostic, the first of its kind to gain FDA approval.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C round brings $30mm to Pathwork Diagnostics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice